Kinnate Biopharma

Nuvalent

This biopharmaceutical company develops targeted small molecule kinase inhibitors for patients with genomically defined cancers such as non-small cell lung cancer.

Crossfire Oncology

This company develops kinase-targeting inhibitors, degraders and degrader-antibody conjugates to treat cancer patients.

Nuvectis Pharma

This biopharmaceutical company develops precision medicines and targeted small molecule therapeutics for patients with advanced cancers and other serious conditions.

KyDo Therapeutics

This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.

Deciphera Pharmaceuticals

This biopharmaceutical company develops and commercialises kinase-inhibiting drugs for patients with cancer, immunological diseases, and neurological conditions.

KyDo

This biotechnology company develops small molecule inhibitors for the treatment of cancer variants in oncology patients.

Black Diamond Therapeutics

This clinical-stage company develops precision oncology medicines and small molecule therapies for patients with genetically defined cancers.

Blueprint Medicines

This biopharmaceutical company develops and commercialises kinase inhibitors for patients with systemic mastocytosis, gastrointestinal stromal tumours and other genomic-driven cancers.